Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. The pharmaceutical compositions of the invention can be administered to a subject, thereby providing methods for inhibiting M. tuberculosis -infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or a M. tuberculosis -infected cell, wherein a T cell is contacted with an APC that is modified to present an hsp110 or grp170 polypeptide and an immunogenic polypeptide associated with a tumor or with the M. tuberculosis -infected cell. Included in the invention are T cells produced by this method and a pharmaceutical composition comprising such T cells. The T cells can be contacted with a M. tuberculosis -infected cell in a method for killing a M. tuberculosis -infected cell, or with a tumor cell in a method for killing a tumor cell.
1. A pharmaceutical composition comprising an isolated stress protein complex and a physiologically acceptable carrier, wherein the stress protein complex comprises a grp170 polypeptide and an immunogenic polypeptide, wherein the grp170 polypeptide is complexed with the immunogenic polypeptide by non-covalent interaction, and wherein the complex has been heated in vitro to approximately 39° C. to approximately 43° C. so as to enhance binding of the grp170 polypeptide to the immunogenic polypeptide.
2. The pharmaceutical composition of claim 1 , wherein the complex is derived from a tumor.
3. The pharmaceutical composition of claim 1 , wherein the complex is derived from a cell infected with an infectious agent.
4. The pharmaceutical composition of claim 1 , wherein the immunogenic polypeptide comprises a cancer antigen.
5. The pharmaceutical composition of claim 4 , wherein the cancer antigen comprises a colon cancer, melanoma or fibrosarcoma antigen.
6. The pharmaceutical composition of claim 1 , wherein the immunogenic polypeptide comprises an infectious disease antigen.
7. The pharmaceutical composition of claim 1 , wherein the complex has been heated to a temperature of about 39-40° C.
8. The pharmaceutical composition of claim 1 , wherein the complex has been heated to a temperature of about 43° C.
9. The pharmaceutical composition of claim 1 , wherein the immunogenic polypeptide is produced by recombinant techniques.
10. A pharmaceutical composition comprising an isolated stress protein complex and a physiologically acceptable carrier, wherein the stress protein complex comprises a grp170 polypeptide and an immunogenic polypeptide, wherein the grp170 polypeptide is complexed with the immunogenic polypeptide by non-covalent interaction, wherein the complex has been heated in vitro to approximately 39° C. to approximately 43° C. so as to enhance binding of the grp170 polypeptide to the immunogenic polypeptide, and wherein the stress protein complex further comprises a polypeptide selected from the group consisting of hsp110, hsp70, hsp90, grp78 and grp94.
11. A method of enhancing the immunogenicity of an isolated stress protein complex comprising heating the stress protein complex in vitro to approximately 39° C. to approximately 43° C., wherein the stress protein complex comprises a grp170 stress polypeptide and an immunogenic polypeptide.
12. The method of claim 11 , wherein the heating comprises heating the stress protein complex to a temperature of 39-40° C.
13. The method of claim 11 , wherein the heating comprises heating the stress protein complex to a temperature of 39° C.
14. The method of claim 11 , wherein the immunogenic polypeptide is a cancer antigen or an infectious disease antigen.
15. A method of enhancing the immunogenicity of an isolated stress protein complex comprising heating the stress protein complex in vitro to approximately 43° C. wherein the stress protein complex comprises a grp170 polypeptide and an immunogenic polypeptide, and wherein the immunogenic polypeptide is a cancer antigen or an infectious disease antigen.
16. The method of claim 15 , wherein the immunogenic polypeptide is an infectious disease antigen.
17. A method of enhancing an immune response to an antigen administered to a subject comprising administering a grp170 polypeptide and the antigen to the subject, wherein the grp170 polypeptide is complexed with the antigen by non-covalent interaction, and wherein the complex has been heated in vitro to approximately 39° C. to approximately 43° C. so as to enhance binding of the grp170 polypeptide to the immunogenic polypeptide.
18. A method for inhibiting tumor growth in a subject, comprising administering to a patient an effective amount of a pharmaceutical composition of claim 4 to elicit an anti-tumor response, and thereby inhibiting tumor growth in the subject.